Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study.

Neurology. 2005 May 10;64(9):1563-72.

PMID:
15883317
2.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team.

Neurology. 2005 May 10;64(9):1553-62.

PMID:
15883316
3.

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team.

Curr Alzheimer Res. 2009 Apr;6(2):144-51.

4.

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C.

Neurology. 2003 Jul 8;61(1):46-54.

PMID:
12847155
5.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group.

Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

PMID:
18672400
6.

Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

Ghochikyan A.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. Review.

7.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

PMID:
22677258
8.

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J.

J Nutr Health Aging. 2009 Jun;13(6):550-7. Erratum in: J Nutr Health Aging. 2010 Jan;14(1):80.

PMID:
19536424
9.

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA.

Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2.

10.

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM.

Neuron. 2003 May 22;38(4):547-54.

11.

Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.

Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC.

J Neurol. 2008 Apr;255(4):567-74. doi: 10.1007/s00415-008-0750-9. Epub 2008 Feb 18.

PMID:
18274807
12.

Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.

Pasquier F, Sadowsky C, Holstein A, Leterme Gle P, Peng Y, Jackson N, Fox NC, Ketter N, Liu E, Ryan JM; ACC-001 (QS-21) Study Team.

J Alzheimers Dis. 2016;51(4):1131-43. doi: 10.3233/JAD-150376.

PMID:
26967206
13.

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.

Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS.

Neurodegener Dis. 2008;5(3-4):194-6. doi: 10.1159/000113700. Epub 2008 Mar 6. Review.

PMID:
18322388
14.

S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.

Zhang W, Zhang W, Li Z, Hao J, Zhang Z, Liu L, Mao N, Miao J, Zhang L.

Pharmacol Biochem Behav. 2012 Jan;100(3):361-9. doi: 10.1016/j.pbb.2011.09.012. Epub 2011 Oct 2.

PMID:
21993310
15.

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T.

J Neurosci. 2004 Jul 14;24(28):6277-82.

16.

Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.

Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, Pickering RM, Nicoll JA, Holmes C, Hugon J, Boche D.

J Pathol. 2015 Apr;235(5):721-30. doi: 10.1002/path.4491. Epub 2015 Jan 7.

PMID:
25430817
17.

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

Brain. 2008 Dec;131(Pt 12):3299-310. doi: 10.1093/brain/awn261. Epub 2008 Oct 25.

PMID:
18953056
18.

Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.

Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S.

Neurology. 2005 Jan 11;64(1):94-101.

PMID:
15642910
19.

An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease.

Koepsell TD, Chi YY, Zhou XH, Lee WW, Ramos EM, Kukull WA.

Neurology. 2007 Nov 6;69(19):1868-72.

PMID:
17984455
20.

Vaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease.

Rosset MB, Lui G, Dansokho C, Chaigneau T, Dorothée G.

J Neuroinflammation. 2015 May 16;12:95. doi: 10.1186/s12974-015-0317-5.

Supplemental Content

Support Center